Immune checkpoint inhibitor therapy resulted in Triple M overlap syndrome in 8 patients at a median of 14.5 days, with 5 requiring mechanical ventilation and all needing additional immunomodulators.
Case Report (n=8)
No
Triple M overlap syndrome is a severe, life-threatening immune-related adverse event of immune checkpoint inhibitors that presents with myocarditis, myositis, and myasthenia gravis, requiring aggressive immunomodulatory therapy beyond corticosteroids.
Immune checkpoint inhibitor-associated Triple M overlap syndrome (TMOS), defined by concurrent myocarditis, myositis, and myasthenia gravis, is a rare but life-threatening immune-related adverse event. We report a single-center case series of 8 consecutive patients who developed TMOS during immune checkpoint inhibitor therapy for solid malignancies between 2023 and 2025. Median age was 76 years and median time to symptom onset was 14.5 days after exposure. All patients had myositis symptoms; 5 required mechanical ventilation and 1 subsequently required tracheostomy. Cardiac involvement was characterized by troponin elevation and frequent electrical abnormalities, including complete atrioventricular block, ventricular tachyarrhythmias, and bundle branch block, despite preserved left ventricular systolic function on imaging. Corticosteroid monotherapy was insufficient in practice, and all patients required additional immunomodulatory therapy. TMOS requires early recognition, close monitoring, and rapid multidisciplinary escalation of care.
Osorio et al. (Mon,) conducted a case report in Triple M overlap syndrome (TMOS) (n=8). Immune checkpoint inhibitors was evaluated. Immune checkpoint inhibitor therapy resulted in Triple M overlap syndrome in 8 patients at a median of 14.5 days, with 5 requiring mechanical ventilation and all needing additional immunomodulators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: